IMMUNOGLOBULIN VARIANTS AND USES THEREOF
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
12 Citations
89 Claims
-
1-81. -81. (canceled)
-
82. An isolated nucleic acid encoding an antibody that binds to human CD20 or an antigen-binding fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
- 8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO;
2 with amino acid substitution S92A. - View Dependent Claims (83, 84, 85, 87, 88)
- 8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO;
-
86. An isolated host cell comprising a first vector comprising a nucleic acid encoding the heavy chain variable region (VH) of an antibody or antigen-binding fragment thereof, and a second vector comprising a nucleic acid encoding the light chain variable region (VL) of the antibody or antigen-binding fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
- 8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO;
2 with amino acid substitution S92A; and
wherein the antibody binds to human CD20.
- 8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO;
-
89. A method of producing an antibody that binds to human CD20 or antigen-binding fragment thereof, comprising culturing a host cell under conditions so that the antibody or antigen-binding fragment is produced, wherein the host cell comprises a first vector and a second vector encoding the antibody or antigen-binding fragment thereof, wherein the first vector comprises a nucleic acid encoding the heavy chain variable region (VH) of the antibody, and the second vector comprises a nucleic acid encoding the light chain variable region (VL) of the antibody, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
- 8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO;
2 with amino acid substitution S92A.
- 8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO;
Specification